Abstract: A power circuit assembly for a vehicle. The power circuit assembly includes a first circuit carrier on which at least two power semiconductor switches are arranged; at least one energy store which provides a high voltage and which can be discharged via at least one discharge resistor; a second circuit carrier on which at least two driver circuits are arranged, which are respectively assigned to one of the at least two power semiconductor switches; and a flexible printed circuit board which includes at least one line and electrically connects the first circuit carrier and the second circuit carrier to one another. An inverter including the power circuit assembly for a vehicle is also described.

Abstract: The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

Abstract: The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

Abstract: The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

Abstract: The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.

Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein L, R1, R2, m and n have the meaning given in claim 1 and which can be used in the form of pharmaceutical compositions.

Abstract: The invention is concerned with (S)-1-{[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile mesylate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV.

Abstract: A transistor arrangement has first and second terminals and a control terminal which sets a current flow between the first and second terminals, and a signal conditioning device which applies a transistor control voltage to the control terminal in a manner dependent on a differential voltage present between the first and second terminals, and a driving apparatus is assigned to the signal conditioning device and switches the latter between at least two operating modes.

Abstract: The present invention relates to crystal forms of mammalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.

Abstract: A control circuit for controlling an electronic circuit, which has a current path through a semiconductor switch and a line; when the semiconductor switch is switched, the inductance of the line and/or of a component in the current path producing an excess voltage between a first and a second current-carrying terminal of the semiconductor switch; the control circuit having a controllable current source for charging or discharging a charge-controlled gate of the semiconductor switch with the aid of a control current, as well as a control unit; the control unit controlling the current source in such a manner, that in the case of a switching operation, the terminal voltage across the current-carrying terminals of the semiconductor switch does not exceed a predefined setpoint terminal voltage.

Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein L, R1, R2, m and n have the meaning given in claim 1 and which can be used in the form of pharmaceutical compositions.

Abstract: A control circuit for controlling an electronic circuit, which has a current path through a semiconductor switch and a line; when the semiconductor switch is switched, the inductance of the line and/or of a component in the current path producing an excess voltage between a first and a second current-carrying terminal of the semiconductor switch; the control circuit having a controllable current source for charging or discharging a charge-controlled gate of the semiconductor switch with the aid of a control current, as well as a control unit; the control unit controlling the current source in such a manner, that in the case of a switching operation, the terminal voltage across the current-carrying terminals of the semiconductor switch does not exceed a predefined setpoint terminal voltage.

Abstract: The invention relates to a transistor arrangement (1) comprising a transistor (10), which is provided with first and second connections (12, 14) and a control connection (16) for controlling a current flow (iD) between said first and second connections (12, 14), a signal processing device (22) exposed to the transistor control voltage (uDS) for admitting said control connection (16) according to a differential voltage (uDS) supplied between the first and second connections (12, 14) and a control device (23) which is associated with the signal processing device (22) and switches it between at least two operating modes. An inverter signal (uWR) causes, for an uWR value=0, an effect in such a way that the transistor (10) is used in the form of a conductor for uDS<0 and is locked for uDS>0. For uWR=uWR, said transistor (10) is permanently conductive.

Abstract: The invention is concerned with (S)-1-{[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile mesylate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV.

Abstract: The present invention relates to crystal forms of mammmalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.